VolitionRX (AMEX:VNRX) Is Now Covered By Maxim Group. What can We Expect?

May 17, 2018 - By Michael Collier

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Investors sentiment decreased to 1.2 in Q4 2017. Its down 5.80, from 7 in 2017Q3. It turned negative, as 3 investors sold VolitionRx Limited shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 4.52 million shares or 51.36% less from 9.30 million shares in 2017Q3 were reported.

Leisure Cap Management invested 0.18% in VolitionRx Limited (NYSEAMERICAN:VNRX). Vanguard Grp Incorporated stated it has 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Creative Planning reported 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Blackrock has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Geode Cap Management Ltd Liability invested in 100,890 shares or 0% of the stock. Knoll Capital Mgmt Lp has invested 0.91% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Northern Tru holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 22,714 shares. Bessemer Gp holds 0% or 10,000 shares in its portfolio. Brown Brothers Harriman & has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Morgan Stanley reported 63,400 shares. Garrison Bradford And Assocs holds 0.04% or 15,500 shares. Lagoda L P, a New York-based fund reported 3.52 million shares. Bridgeway Mngmt has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Commercial Bank Of Mellon holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 10,335 shares. Royal Savings Bank Of Canada reported 14,007 shares or 0% of all its holdings.

Why Has Maxim Group Given VolitionRX (AMEX:VNRX) a $6.0000 Price Target

Analysts at Maxim Group has initiated coverage on shares of VolitionRX (AMEX:VNRX) in a note revealed to clients on Wednesday, 16 May. The financial firm set Buy rating on the $67.57M market cap company.

The stock increased 8.70% or $0.18 during the last trading session, reaching $2.25. About 145,762 shares traded or 4.78% up from the average. VolitionRx Limited (AMEX:VNRX) has declined 42.82% since May 17, 2017 and is downtrending. It has underperformed by 54.37% the S&P500.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on August, 8. They expect $-0.17 earnings per share, down 30.77 % or $0.04 from last year’s $-0.13 per share. After $-0.17 actual earnings per share reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $67.57 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.